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Mobilized Peripheral Blood Stem Cells Versus Unstimulated
Bone Marrow As a Graft Source for T-Cell–Replete
Haploidentical Donor Transplantation Using
Post-Transplant Cyclophosphamide
Asad Bashey, Mei-Jie Zhang, Shannon R. McCurdy, Andrew St. Martin, Trevor Argall, Claudio Anasetti, Stefan O.
Ciurea, Omotayo Fasan, Sameh Gaballa, Mehdi Hamadani, Pashna Munshi, Monzr M. Al Malki, Ryotaro
Nakamura, Paul V. O’Donnell, Miguel-Angel Perales, Kavita Raj, Rizwan Romee, Scott Rowley, Vanderson Rocha,
Rachel B. Salit, Melhem Solh, Robert J. Soiffer, Ephraim Joseph Fuchs, and Mary Eapen
A B S T R A C T
Purpose
T-cell–replete HLA-haploidentical donor hematopoietic transplantation using post-transplant cy-
clophosphamidewas originally described using bonemarrow (BM).With increasing use ofmobilized
peripheral blood (PB), we compared transplant outcomes after PB and BM transplants.
Patients and Methods
A total of 681 patients with hematologic malignancy who underwent transplantation in the United
States between 2009 and 2014 received BM (n = 481) or PB (n = 190) grafts. Cox regression models
were built to examine differences in transplant outcomes by graft type, adjusting for patient,
disease, and transplant characteristics.
Results
Hematopoietic recovery was similar after transplantation of BM and PB (28-day neutrophil recovery,
88% v 93%, P = .07; 100-day platelet recovery, 88% v 85%, P = .33). Risks of grade 2 to 4 acute
(hazard ratio [HR], 0.45; P , .001) and chronic (HR, 0.35; P , .001) graft-versus-host disease were
lower with transplantation of BM compared with PB. There were no signiﬁcant differences in overall
survival by graft type (HR, 0.99; P = .98), with rates of 54% and 57% at 2 years after transplan-
tation of BM and PB, respectively. There were no differences in nonrelapsemortality risks (HR, 0.92;
P = .74) but relapse risks were higher after transplantation of BM (HR, 1.49; P = .009). Additional
exploration conﬁrmed that the higher relapse risks after transplantation of BM were limited to
patients with leukemia (HR, 1.73; P = .002) and not lymphoma (HR, 0.87; P = .64).
Conclusion
PB and BM grafts are suitable for haploidentical transplantation with the post-transplant cyclo-
phosphamide approach but with differing patterns of treatment failure. Although, to our knowledge,
this is the most comprehensive comparison, these ﬁndings must be validated in a randomized
prospective comparison with adequate follow-up.
J Clin Oncol 35:3002-3009. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Allogeneic hematopoietic cell transplantation
using a T-cell–replete HLA-haploidentical donor
transplantation, with post-transplant cyclophos-
phamide to control alloreactivity, has recently been
demonstrated as a safe and effective alternative in
patients who lack timely access to amatched related
or unrelated donor.1-5 In retrospective comparisons
adjusted for confounding covariables, recipients of
transplants using HLA-haploidentical donors with
a post-transplant cyclophosphamide strategy
were shown to have equivalent survival and
nonrelapse mortality to recipients of matched
related and matched unrelated donor trans-
plants and with evidence of lower incidence
and severity of chronic graft-versus-host dis-
ease (GVHD).3,4,6,7
As originally developed by the Baltimore
group, HLA-haploidentical transplantation with
post-transplant cyclophosphamide was performed
using a bonemarrow (BM) graft.Mobilized peripheral
blood (PB) grafts are consideredmore convenient and
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are widely used for HLA-matched related and unrelated donor
transplantations. In these patients, prospective comparisons
have demonstrated similar outcomes to BM transplants except
more rapid hematopoietic recovery and a higher incidence of
chronic GVHD with PB when using myeloablative conditioning
and conventional GVHD prophylaxis.8,9 For HLA-haploidentical
transplantation with post-transplant cyclophosphamide, single
centers have reported relatively good outcomes using mobilized
PB.10-14 In a recent small, matched-pair comparison, nonablative
haploidentical transplants with post-transplant cyclophospha-
mide with PB had similar times to engraftment, rates of acute and
chronic GVHD, and overall survival but lower relapse compared
with BM.15 In the absence of prospective trials of outcomes after
haploidentical transplants using post-transplant cyclophospha-
mide and PB grafts, we used data reported to the Center for
International Blood and Marrow Transplant Research to study
outcomes after transplantation of PB compared with BM for
hematologic malignancy.
PATIENTS AND METHODS
Patients
The Center for International Blood and Marrow Transplant Research
is a group of over 350 transplant centers that contribute data prospectively
on consecutive transplants performed at each individual center. Forty-two
centers contributed patients, and transplants were performed between
2009 and 2014 in the United States. Eligible patients were$ 18 years of age
with acute myeloid leukemia, acute lymphoblastic leukemia, myelodys-
plastic syndrome, non-Hodgkin lymphoma, or Hodgkin lymphoma. All
received BM or PB from haploidentical related donors and a uniform
GVHD prophylaxis regimen (tacrolimus or cyclosporine with mycophe-
nolate and post-transplant cyclophosphamide). The reduced-intensity
conditioning regimen was uniform for both graft types (total-body ir-
radiation [TBI] 2 Gy, cyclophosphamide 29mg/kg, ﬂudarabine 150mg/m2).
Myeloablative regimens included TBI ($ 10 Gy with ﬂudarabine or cy-
clophosphamide) or busulfan and cyclophosphamide with or without
ﬂudarabine. Excluded were transplant regimens that were melphalan-based
(n = 109) and busulfan with ﬂudarabine (n = 13) because these were ex-
clusively used for BM transplants. Also excludedwere regimens that included
antithymocyte globulin or alemtuzumab (n = 92) or CD34 selected PB grafts
(n = 139). Patients provided written informed consent for research. The
institutional review board of the National MarrowDonor Program approved
this study.
End Points
The primary end point was overall survival. Death from any cause was
considered an event. Neutrophil recovery was deﬁned as achieving an
absolute neutrophil count of $ 0.5 3 109/L for 3 consecutive days, and
platelet recovery was deﬁned as platelets $ 20 3 109/L, unsupported by
transfusion for 7 days. Primary and secondary graft failures were con-
sidered as a single outcome. Primary graft failure was deﬁned as failure to
achieve an absolute neutrophil count of $ 0.5 3 109/L for 3 consecutive
days or donor chimerism, 5% (PB CD3+ or BM). Secondary graft failure
was deﬁned as initial donor engraftment followed by graft loss, evidenced
by a persistent decline in the absolute neutrophil count (, 0.53 109/L) or
loss of donor chimerism, 5% or a second transplantation in patients with
documented clinical remission.16 Grades 2 to 4 and 3 to 4 acute GVHD and
chronic GVHD were based on reports from each transplant center using
standard criteria.17,18 Relapse/progression was deﬁned as disease re-
currence (morphologic, cytogenetic, or molecular) or progression, and
nonrelapse mortality was deﬁned as death in remission. Progression-free
survival (PFS) was deﬁned as surviving in remission (relapse/progression
or death were considered events). GVHD-free, relapse-free survival
(GRFS) events included grade 3 to 4 acute GVHD, chronic GVHD
requiring systemic therapy, relapse or progression, or death from any
cause within the ﬁrst year after transplantation.19 Surviving patients
were censored at last follow-up.
Statistical Methods
Differences between groups were compared using the x2 statistic for
categorical variables. The probabilities of overall survival, PFS, and GRFS
were calculated using the Kaplan-Meier estimator.20 The probabilities of
neutrophil and platelet recovery, acute and chronic GVHD, nonrelapse
mortality, and relapse/progression were calculated using the cumulative
incidence estimator to accommodate competing risks.21 Cox regression
models were built to study the effect of graft type (BM v PB) and other
factors associated with overall mortality, grade 2 to 4 and grade 3 to 4 acute
GVHD, chronic GVHD, relapse/progression, nonrelapse mortality and
treatment failure (inverse of PFS), and GRFS.22 Variables tested included:
graft type, age, sex, performance score, hematopoietic cell transplant
comorbidity index (HCT-CI) score, cytomegalovirus (CMV) serostatus,
disease, disease status, disease risk index (DRI; a composite of disease,
disease status at transplant, cytogenetic risk for leukemias and disease, and
disease status at transplant for lymphomas),23 transplant conditioning
regimen intensity, and transplant period. All variables tested met the
assumptions for proportionality, and there were no ﬁrst-order interactions
between graft type and other variables held in the ﬁnal multivariable
model. All variables that attained a P value # .05 were held in the ﬁnal
multivariable model, with the exception of the variable for graft type that
was held in all steps of model building and the ﬁnal model regardless of the
level of signiﬁcance. Transplant center effect on survival was tested using
the frailty approach.24 All P values are two sided. All analyses were per-
formed using SAS (version 9.4; SAS Institute, Cary, NC).
RESULTS
Patient, Disease, and Transplant Characteristics
The characteristics of the study population by graft type are
listed in Table 1. The median age of BM recipients was 58 years
(range, 18 to 76 years) and that of PB recipients was 47 years
(range, 19 to 73 years). Compared with recipients of BM, recipients
of PB were younger and less likely to have performance scores of 90
or 100, to have HCT-CI scores of 0 to 2, to be CMV seronegative,
and to have received a reduced-intensity conditioning regimen.
Recipients of BM were less likely to have undergone transplantation
for acutemyeloid leukemia (AML) and less likely to have a high DRI.
The majority of BM recipients received a reduced-intensity con-
ditioning regimen that was uniform for both graft types. Although
myeloablative regimens were restricted to TBI $ 10 Gy with ﬂu-
darabine or cyclophosphamide and busulfan and cyclophosphamide
with or without ﬂudarabine, BM recipients were less likely to receive
a TBI-containing regimen compared with PB recipients. Because
the majority of PB transplants were performed after 2011, the
median follow-up of PB recipients was 20 months (range, 6 to
72 months) compared with 35 months (range, 3 to 74 months)
for BM recipients.
Hematopoietic Recovery
The median times to neutrophil and platelet recovery were
slower after transplantation of BM compared with PB (17 v 16 days
for neutrophils, P , .001; and 26 v 25 days for platelets, P = .03).
jco.org © 2017 by American Society of Clinical Oncology 3003
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Despite this, there were no signiﬁcant differences in day-28 rates
of neutrophil recovery after transplantation of BM and PB grafts
(88%; 95% CI, 85 to 91; and 93%; 95% CI, 89 to 96, respectively;
P = .07) and in day-100 rates of platelet recovery (88%; 95% CI,
85 to 91; and 85%; 95% CI, 80 to 90; P = .33). The 1-year cu-
mulative incidence of primary or secondary graft failure rates after
transplantation of BM and PB were 9% (95% CI, 7 to 12) and 12%
(95% CI, 8 to 17; P = .23), respectively.
GVHD
Compared with transplantation of PB, grade 2 to 4 acute
GVHD was lower after transplantation of BM, but there were no
differences in risks of grade 3 to 4 acute GVHD (Table 2; Fig 1A).
Independent of graft type, grade 2 to 4 acute GVHD was higher
with reduced-intensity regimens (HR, 1.51; 95% CI, 1.09 to 2.10;
P = .01). The 6-month incidence of grade 2 to 4 acute GVHD was
25% (95% CI, 21% to 29%) and 42% (95% CI, 35% to 50%) after
transplantation of BM and PB, respectively. Chronic GVHD risks
were also lower after transplantation of BM (Table 2). Risks were
higher for patients with performance scores , 90 (HR, 1.50; 95%
CI, 1.08 to 2.08; P = .01). The 2-year incidence of chronic GVHD
was 20% (95% CI, 16% to 24%) and 41% (95% CI, 33% to 48%),
after transplantation of BM and PB, respectively (Fig 1B). Despite
differences in chronic GVHD risk by graft type, there were no
differences in its severity by graft type (P = .64). Among BM
recipients (n = 90) with chronic GVHD, severity was graded as
mild for 62%, moderate for 28%, and severe for 10%. Corre-
sponding severity rates for PB recipients (n = 78) was 58%, 30%,
and 12%, respectively. Chronic GVHD rates were lower with BM
Table 1. Patient, Disease, and Transplant Characteristics
Characteristic Bone Marrow, No. (%) Peripheral Blood, No. (%) P
No. 496 191
Age, years , .001
18-50 197 (40) 106 (55)
51-76 299 (60) 85 (45)
Sex .34
Male 290 (58) 104 (54)
Female 206 (42) 87 (46)
Performance score , .001
90-100 344 (69) 93 (49)
# 80 125 (25) 96 (50)
Not reported 27 (5) 2 (1)
Transplant comorbidity index , .001
0-2 340 (69) 98 (51)
$ 3 156 (31) 93 (49)
Cytomegalovirus serostatus .03
Negative 221 (45) 64 (34)
Positive 273 (55) 126 (66)
Not reported 2 (, 1) 1 (, 1)
Disease , .001
Acute myeloid leukemia 193 (39) 107 (56)
Acute lymphoblastic leukemia 70 (14) 29 (15)
Myelodysplastic syndrome 40 (8) 18 (9)
Non-Hodgkin lymphoma 143 (29) 27 (14)
Hodgkin lymphoma 50 (10) 10 (5)
Disease status .17
First complete remission 245 (49) 80 (42)
Second complete remission 71 (14) 28 (15)
Relapse, refractory anemia with blasts, partial response/
chemoresistant
180 (36) 83 (43)
Disease risk index , .001
Low 57 (11) 18 (9)
Intermediate 329 (66) 92 (48)
High 110 (22) 81 (42)
Conditioning regimen , .001
Busulfan, cyclophosphamide with or without ﬂudarabine 65 (13) 45 (24)
TBI ($ 10 Gy) plus cyclophosphamide 15 (3) 5 (3)
TBI ($ 10 Gy) plus ﬂudarabine 11 (2) 53 (28)
TBI (2 Gy) plus cyclophosphamide plus ﬂudarabine 405 (82) 88 (46)
Graft-versus-host disease prophylaxis —
Calcineurin inhibitor, mycophenolate, post-transplant
cyclophosphamide
496 (100) 191 (100)
Planned use of growth factor
Yes 369 (74) 95 (50) , .001
No 16 (3) 13 (7)
Not reported 111 (22) 83 (43)
Abbreviation: TBI, total-body irradiation.
3004 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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grafts in the setting of both myeloablative (HR, 0.35; 95% CI, 0.23
to 0.52; P, .001) and reduced-intensity (HR, 0.28; 95%CI, 0.14 to
0.55; P , .001) regimens.
Overall Survival
The risks of overall mortality did not differ by graft type
(Table 2; Fig 2). Other factors associated with higher mortality
included age, older than 55 years of age (HR, 1.72; 95% CI, 1.34
to 2.21; P , .001), CMV seropositivity (HR, 1.47; 95% CI, 1.15
to 1.89; P = .002), high DRI (HR, 2.12; 95% CI, 1.31 to 3.45;
P , .001), and myeloablative conditioning regimen (HR, 1.39;
95% CI, 1.04 to 1.85; P = .03). The effect of graft type on survival
was further tested, adjusting for age, performance score, HCT-CI
score, CMV seropositivity, disease type, disease status, DRI, and
transplant conditioning regimen; consistent with the main model,
overall mortality risks did not differ by graft type (Appendix Table
A1, online only). The effect of the transplant center on overall
survival was explored, and no relationship was found (P = .82).
There were no differences in causes of death by graft type (P = .13);
recurrent disease was the most common cause of death, accounting
for 69% of deaths in BM recipients and 67% in PB recipients. There
were no differences in proportion of deaths attributed to GVHD,
infection, interstitial pneumonitis, or organ failure by graft type.
Nonrelapse Mortality
The risk of nonrelapse mortality also did not differ by graft
type (Table 2; Fig 3A). Independent of graft type, nonrelapse
mortality risks were higher for patients who were older than 55
years of age (HR, 2.56; 95% CI, 1.67 to 3.92; P, .001), were CMV
seropositive (HR, 1.96; 95% CI, 1.26 to 3.04; P = .003), and
received myeloablative conditioning regimens (HR, 1.86; 95% CI,
1.16 to 3.00; P = .01).
Relapse/Progression
Relapse/progression was higher after BM compared with PB
transplants (Table 2; Fig 3B), adjusted for an intermediate (HR,
2.28; 95% CI, 1.32 to 3.94; P = .003) and a high (HR, 3.81; 95% CI,
2.17 to 6.69; P , .001) DRI. The effect of graft type on relapse/
progression may be inﬂuenced by disease type (P = .05); therefore,
in subset analysis, the effect of disease type was tested separately
for leukemia/myelodysplastic syndrome (MDS) and lymphoma.
For patients with leukemia/MDS (predominantly AML), relapse
risks were higher with transplantation of BM compared with PB
(HR, 1.73; 95% CI, 1.23 to 2.44; P = .002) after adjusting for DRI.
Although there were no differences in the proportion of patients
with de novo AML, BM recipients were older (difference of 8 years
in median age), but had better performance and HCT-CI scores,
were more likely to be in remission at transplantation, and were
more likely to have received reduced-intensity conditioning
(Appendix Table A2, online only). We did not observe differences
in relapse risks by graft type for patients with lymphoma (HR, 0.87;
95% CI, 0.48 to 1.58; P = .64). Transplant conditioning regimen
intensity was not associated with relapse/progression (P = .09).
Because higher risk of relapse/progression with transplantation
of BM could potentially be attributed to lower GVHD rates, acute
and chronic GVHD were tested as time-dependent covariables to
study graft-versus-tumor effects. Relapse risks were higher after
transplantation of BM, adjusting for acute GVHD (HR, 2.22;
P = .02), chronic GVHD (HR, 1.92; P = .02), and acute and
chronic GVHD (HR, 2.13; P = .01), suggesting that the lower
Table 2. Effect of Graft Type on Transplant Outcomes
Outcomes Events/Evaluable, No. Hazard Ratio (95% CI) P
Grade II-IV acute GVHD*
Peripheral blood 84/190 1.00
Bone marrow 137/481 0.45 (0.34 to 0.61) , .001
Grade III-IV acute GVHD
Peripheral blood 23/190 1.00
Bone marrow 39/481 0.61 (0.36 to 1.02) .06
Chronic GVHD†
Peripheral blood 78/184 1.00
Bone marrow 90/486 0.35 (0.25 to 0.49) , .001
Overall mortality‡
Peripheral blood 81/191 1.00
Bone marrow 221/496 0.99 (0.75 to 1.33) .98
Nonrelapse mortality§
Peripheral blood 32/191 1.00
Bone marrow 73/496 0.92 (0.57 to 1.48) .74
Relapse/progressionk
Peripheral blood 32/191 1.00
Bone marrow 73/496 1.49 (1.10 to 2.01) .009
Progression-free survivalk
Peripheral blood 32/191 1.00
Bone marrow 73/496 1.21 (0.95 to 1.56) .13
Abbreviation: GVHD, graft-versus-host disease.
*Adjusted for conditioning regimen intensity.
†Adjusted for performance score.
‡Adjusted for age, cytomegalovirus serostatus, disease risk index, and conditioning regimen intensity.
§Adjusted for age, cytomegalovirus serostatus, and conditioning regimen intensity.
kAdjusted for age, cytomegalovirus serostatus, and disease risk index.
jco.org © 2017 by American Society of Clinical Oncology 3005
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relapse rate observed using PB could not adequately be explained by
the higher rates of GVHD associated with this graft source.
PFS
Although the overall PFS did not differ by graft type (Table 2),
the 2-year probabilities of PFS adjusted for age, CMV serostatus,
and DRI support differences by graft type (Fig 4). PFS was worse
for patients who were older than 55 years of age (HR, 1.31; 95% CI,
1.06 to 1.61; P = .01), had CMV seropositivity (HR, 1.26; 95% CI,
1.02 to 1.57; P = .03), had an intermediate DRI (HR, 1.59; 95% CI,
1.06 to 2.40; P = .03), and had a high DRI (HR, 2.46; 95% CI, 1.61
to 3.77; P , .001). Because the effect of graft type may be
inﬂuenced by disease type (P = .05), PFS was studied separately for
leukemia/MDS and lymphoma. For patients with leukemia/MDS
(predominantly AML), PFS was lower with transplantation of BM
(HR, 1.35; 95% CI, 1.01 to 1.80; P = .04). We did not observe
differences in PFS by graft type for lymphoma (HR, 0.78; 95% CI,
0.49 to 1.27; P = .32). Transplant conditioning regimen intensity
was not associated with PFS (P = .18).
GVHD-Free Relapse-Free Survival
Four hundred seventy-three of 496 BM and 182 of 191 PB
recipients were evaluable for GRFS. GRFS was higher after BM
compared with PB transplants (HR, 0.75; 95% CI, 0.61 to 0.92;
P = .006) after adjusting for performance score and DRI, the other
factors associated with GRFS. The 1-year adjusted probability
of GRFS was 41% (95% CI, 37 to 45) and 27% (95% CI, 21 to 34)
after transplantation of BM and PB, respectively (P , .001).
Relapse was the predominant event in BM recipients (58%), and
acute grade 3 to 4 and chronic GVHD requiring systemic treatment
was the predominant event in PB recipients (46%).
DISCUSSION
To our knowledge, this was the largest analysis that compared
outcomes for T-cell–replete haploidentical-related donor trans-
plant with post-transplant cyclophosphamide using either BM or
PB graft, adjusted for patient and disease characteristics that were
associated with these outcomes to correct for imbalances between
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Fig 1. (A) The 6-month incidence of grades 2
to 4 (left panel) acute graft-versus-host disease
(GVHD) adjusted for conditioning regimen in-
tensity were 25% (95% CI, 21% to 29%) and
42% (95% CI, 35% to 50%) after bone marrow
(BM) and peripheral blood (PB) transplants, re-
spectively. The 6-month incidence of grades
3 to 4 (right panel) acute GVHD adjusted for
conditioning regimen intensity were 7% (95%
CI, 5% to 10%) and 10% (95% CI, 6% to 15%)
after BM and PB transplants, respectively. (B)
The 2-year incidence of chronic GVHD adjusted
for performance score were 20% (95%CI, 16%
to 24%) and 41% (95% CI, 33% to 48%) after
BM and PB transplants, respectively.
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the treatment groups. Heterogeneity of transplant characteristics of
the study population was limited by including a single reduced-
intensity conditioning regimen (Baltimore regimen), one non-
irradiation myeloablative regimen (busulfan and cyclophospha-
mide with or without ﬂudarabine), and TBI-containing ($ 10 Gy)
regimen with ﬂudarabine or cyclophosphamide, and all pa-
tients received uniform GVHD prophylaxis (calcineurin inhibitor,
mycophenolate, and post-transplant cyclophosphamide). Because PB
transplants were more recent, with themajority being performed after
2011, outcomes were censored at 2 years to accommodate differences
in the length of follow-up of patients who received BM and PB. After
a carefully controlled analysis, we did not observe a difference in
hematopoietic recovery, nonrelapse mortality, or survival after
transplantation of BM compared with PB grafts. However, acute
and chronic GVHD risks were higher after transplantation of PB,
and relapse risks were higher after transplantation of BM for
patients with leukemia/MDS but not lymphoma. Consequently,
2-year PFS was higher with PB compared with BM trans-
plants. Yet, GRFS was signiﬁcantly better after transplantation
of BM. Most BM recipients, including those with leukemia/
MDS, received a reduced-intensity conditioning regimen, which
may in part have contributed to higher relapse risk.25 Because
nonrelapse mortality risks were modest after both BM and PB
transplants, the higher relapse risk was not offset by lower
nonrelapse mortality in the BM group. Lower relapse rates after PB
transplants could not be accounted for by higher GVHD with this
graft.
The results demonstrate that there was no difference in he-
matopoietic recovery between the graft types. Similar results have
been demonstrated in smaller comparisons15,26,27 and contrast
with the ﬁnding that in the matched related and unrelated donor
setting, neutrophil recovery occurs 4 to 6 days earlier and platelet
recovery occurs 6 to 8 days earlier with PB.8,28,29 We hypothesize
that the much smaller difference in hematopoietic recovery times
between PB and BM in haploidentical-related donor transplants
may be the result of the use of 100 mg/kg of cyclophosphamide
post-transplant and in part to the use of growth factor, which was
more common in the setting of BM transplants. In this regard, it is
notable that a recent trial of post-transplant cyclophosphamide for
HLA-matched related or unrelated donor PB transplantation30,31
also reported similar median times to neutrophil recovery. We did
not ﬁnd a difference in graft failure rates after transplantation of
BM and PB. This differs from the Blood and Marrow Transplant
Clinical Trials Network trial where, in the setting of myeloablative
conditioning, transplantation of BM from unrelated donors was
associated with higher graft failure.9 Differences between that trial
and the current analysis may relate to the fact that ours was limited
to mismatched related donors, a large number of nonablative
transplants, and use of post-transplant cyclophosphamide. Our
results must also be interpreted with caution because post-
transplant lineage-speciﬁc chimerism data were not available for
all patients.
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Fig 3. (A) The 2-year incidence of nonrelapse mortality adjusted for age, cytomegalovirus serostatus, and transplant conditioning regimen intensity was 17% (95% CI,
13% to 21%) and 16% (95% CI, 11% to 22%) after bone marrow (BM) and peripheral blood (PB) transplants, respectively. (B) The 2-year incidence of relapse/progression
adjusted for disease risk index was 45% (95% CI, 41% to 50%) and 28% (95% CI, 22% to 34%) after BM and PB transplants.
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Fig 2. The 2-year probabilities of overall survival adjusted for age, cytomega-
lovirus serostatus, disease risk index, and transplant conditioning regimen in-
tensity were 54% (95% CI, 49% to 59%) and 57% (95% CI, 49% to 65%) after
bone marrow (BM) and peripheral blood (PB) transplants.
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Acute grade 2 to 4 but not grade 3 to 4 acute GVHD was higher
with PB and consistent with that reported by the European Group for
Blood and Marrow Transplantation32 but differed from reports with
substantially fewer patients that failed to show higher grade 2 to 4
acute GVHDwith PB.12,15 The higher overall chronic GVHD after PB
transplants in the current analysis also differed from the smaller
reports12,15 and the larger series fromEurope.32 The reason behind the
differences between our study and others is unclear other than ours
was a larger population and all patients received a uniform GVHD
prophylaxis regimen that consisted of calcineurin inhibitor, myco-
phenolate, and cyclophosphamide post-transplant. Because choice of
graft type differed by transplanting center, differences in attribution of
clinical ﬁndings to GVHD versus other etiologies and in assessments
between centers cannot be eliminated as possible contributing factors
to the differences between ours and the other reports. We did not
assess the functional health of long-term survivors, which may be
affected by a higher incidence of chronic GVHD.33
Although we performed a careful comparison adjusting for
factors associated with transplant outcomes, there are likely to be
several unknown and unmeasured factors that were not tested. For
example, data on molecular factors associated with AML prognosis
were available on only a small subset of patients and therefore
could not be adequately adjusted for. We do not have data on
immune reconstitution, a limitation of our analysis. Our results
indicate that both BM and PB grafts are valid options for
haploidentical-related donor transplantation for adults with he-
matologic malignancy and ideally must be studied further in the
setting of a randomized trial. The lower relapse risk with trans-
plantation of PB was not associated with better survival in the
short-term, underscoring the importance of follow-up beyond the
2-year period.
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Appendix
Table A1. Effect of Graft Type on Transplant Outcomes Adjusted for Age,
Performance Score, Hematopoietic Cell Transplant Comorbidity Score, Cy-
tomegalovirus Seropositivity, Disease, Disease Status, Disease Risk Index,
and Conditioning Regimen
Outcomes Hazard Ratio (95% CI) P
Grade II-IV acute GVHD
Peripheral blood 1.00
Bone marrow 0.49 (0.36 to 0.68) , .001
Grade III-IV acute GVHD
Peripheral blood 1.00
Bone marrow 0.84 (0.45 to 1.57) .59
Chronic GVHD
Peripheral blood 1.00
Bone marrow 0.34 (0.24 to 0.49) , .001
Overall mortality
Peripheral blood 1.00
Bone marrow 1.02 (0.75 to 1.38) .90
Nonrelapse mortality
Peripheral blood 1.00
Bone marrow 0.93 (0.56 to 1.56) .78
Relapse/progression
Peripheral blood 1.00
Bone marrow 1.45 (1.04 to 2.02) .03
Progression-free survival
Peripheral blood 1.00
Bone marrow 1.27 (0.96 to 1.67) .09
Abbreviation: GVHD, graft-versus-host disease.
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Table A2. Characteristics of Patients With Acute Myeloid Leukemia
Characteristics Bone Marrow Peripheral Blood P
No. 193 107
Age, years , .001
Median (range) 57 (18-76) 49 (19-73)
18-50 67 (35) 59 (55)
51-76 126 (65) 48 (45)
Sex .15
Male 107 (55) 50 (47)
Female 86 (44) 57 (53)
Performance score , .001
90-100 128 (66) 46 (43)
# 80 49 (25) 61 (57)
Not reported 16 (8) __
Transplant comorbidity index .001
0-2 131 (68) 52 (49)
$ 3 62 (32) 55 (51)
Cytomegalovirus serostatus .05
Negative 78 (40) 30 (28)
Positive 115 (60) 76 (71)
Not reported __ 1 (, 1)
Type of acute myeloid leukemia .71
de Novo 148 (77) 80 (75)
Secondary 45 (23) 27 (25)
Disease status , .001
First complete remission 112 (58) 56 (52)
Second complete remission 53 (27) 16 (15)
Relapse 28 (15) 35 (33)
Disease risk index , .001
Low 9 (5) 9 (8)
Intermediate 149 (77) 57 (53)
High 35 (18) 41 (38)
Conditioning regimen , .001
Busulfan, cyclophosphamide with or without ﬂudarabine 47 (24) 30 (28)
TBI ($ 10 Gy) plus cyclophosphamide 1 (, 1) __
TBI ($ 10 Gy) plus ﬂudarabine 4 (2) 33 (31)
TBI (20 Gy) plus cyclophosphamide + ﬂudarabine 141 (73) 44 (41)
NOTE. Data are No. (%) unless otherwise indicated.
Abbreviation: TBI, total-body irradiation.
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